Welcome to our dedicated page for Cellyan Biotechnology news (Ticker: HKPD), a resource for investors and traders seeking the latest updates and insights on Cellyan Biotechnology stock.
Cellyan Biotechnology Co., Ltd. reports developments tied to its Hong Kong-based OTC pharmaceutical cross-border e-commerce supply chain business. The company, formerly Hong Kong Pharma Digital Technology Holdings Limited, operates supply chain services through Joint Cross Border Logistics Company Limited and OTC pharmaceutical procurement and distribution through V-Alliance Technology Supplies Limited.
Recurring news for HKPD includes segment financial results, Nasdaq trading and listing-compliance updates, governance actions from shareholder meetings, changes to the company name and share structure, equity incentive matters, and capital-market activity following its initial public offering of ordinary shares on the Nasdaq Capital Market.
Cellyan Biotechnology (Nasdaq: HKPD) received a Nasdaq notice dated Jan 12, 2026 that its closing bid price was below the $1.00 minimum for 30 consecutive business days (Nov 26, 2025–Jan 9, 2026), resulting in noncompliance with Nasdaq rule 5550(a)(2).
The company’s listing remains active and trading is uninterrupted. Cellyan has a 180-calendar-day cure period until July 13, 2026 to regain a $1.00 closing bid for 10 consecutive business days or seek a second 180-day period by meeting other Capital Market listing standards and notifying Nasdaq.
Hong Kong Pharma Digital (NASDAQ: HKPD) announced that at its December 12, 2025 annual meeting all proposals were approved. Key corporate actions approved include: an increase of authorized share capital from US$100,000 to US$1,000,000 (100M to 1,000M shares), re-designation to Class A and Class B ordinary shares, a reverse share split/share consolidation, the repurchase of 7,150,000 Class A ordinary shares from TUTU Business Services Limited with issuance of Class B shares, adoption of a 2025 Equity Incentive Plan, re-election of five directors, appointment of Onestop Assurance PAC as auditor, and a corporate name change to Cellyan Biotechnology Co., Ltd.
Hong Kong Pharma Digital Technology (NASDAQ: HKPD) reported strong financial results for H1 2024 (ended September 30), with net revenues reaching $11.09 million, up 58.9% year-over-year. The growth was primarily driven by:
- Supply Chain Services revenue: $6.33M (+36.3% YoY)
- Procurement and Distribution: $4.76M (+102.7% YoY)
- Consignment Sales: $2,210 (down from $15,327)
The company's gross profit increased 42.6% to $1.91M, while total expenses rose to $10.07M. Despite higher costs, net income surged 232.6% to $828,559, demonstrating operational efficiency and successful market expansion in the OTC pharmaceutical cross-border e-commerce sector.
Hong Kong Pharma Digital Technology Holdings (NASDAQ: HKPD), a leading OTC pharmaceutical cross-border e-commerce supply chain services provider in Hong Kong, has completed its initial public offering. The company sold 1,403,685 ordinary shares at $4.00 per share, comprising 1,000,000 shares from the company and 403,685 from selling shareholders.
The IPO generated total gross proceeds of $5,614,740, with the company receiving $4,000,000 and selling shareholders receiving $1,614,740, before deducting underwriting costs. Trading began on Nasdaq Capital Market on January 15, 2025, under 'HKPD'. The company granted underwriters a 45-day option to purchase up to 150,000 additional shares.
The net proceeds will fund development of supply chain ERP systems, warehouse equipment procurement, sales and marketing team expansion, and working capital needs. Bancroft Capital led the underwriting, with Eddid Securities USA as co-underwriter.